TRANSCATHETER AORTIC VALVE IMPLANTATION AND OPEN AORTIC SURGERY: COMPARATIVE ASSESSMENT OF RESULTS

Aim. The aim of this study is to compare hospital and long-term outcomes in patients with low surgical risk after aortic stenosis correction in surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI).

Materials and methods. Patients with aortic stenosis (AS) were included in the study. The main criterion for inclusion - the presence of indications for surgical correction of an isolated aortic valve defect. The first group included patients after TAVI (n = 11). As a control group, patients who underwent surgical correction aortic stenosis (n = 23). The TAVI group used non-repositories CoreValve (Medtronic) and repositioned Lotus (Boston Scientific) valves. Biological prosthesis Uniline (KemKor) was used in the group of surgical patients. The efficacy of the interventions was evaluated at the hospital and annual follow-up, based on the analysis of the combined endpoint, and major adverse cardiovascular events.

Results. The mean age of the patients was 66.9±5.7 years in the SAVR group and 75.3±4.1 years in the TAVI group (р=0,003). The average score for EuroSCORE II was 3.49±0.3 in the SAVR group and 3.93±1.2 in the TAVI group (р=0,31). Repositionable and non-repositionable valves were implanted in 2 and 9 cases, respectively. The combined endpoint was noted in one patient in the TAVI group and in four patients in the SAVR group according to the annual observation results. There are three (13%) fatal outcomes in the surgical prosthesis group.

Conclusion. The possibility of using TAVI in low-risk patients with aortic stenosis was demonstrated on the basis of comparable results of evaluating efficacy and safety with SAVR in 1-year follow-up.

1. Iung B., Baron G., Butchart E.G., et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24:1231-43. DOI: 10.1016/S0195-668X(03)00201-X

2. Buellesfeld L., Gerckens U., Schuler G. et al. 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. J Am Col. Cardiol. 2011; 57:1650 DOI:10.1016/j.jacc.2010.11.044

3. Odarenko Yu.N., Rutkovskaya N.V., Rogulina N.V. et al. An analysis of 23 years of experience in the use of xeno-aortic epoxy-processing bioprostheses in the surgery of mitral heart defects. The study of the factors of the recipient from the standpoint of influence on the development of calcium degeneration. Complex problems of cardiovascular diseases. 2015;4:17-25. [in Russian] DOI: 10.17802/2306-1278-2015-4-17-25

4. Holmes DR Jr, Nishimura RA, Grover FL, et al. STS/ACC TVT Registry. Annual оutcomes with transcatheter valve therapy: From the STS/ACC TVT Registry. J Am Coll Cardiol, 2015; 66:2813-23. DOI:10.1016/j.jacc.2015.10.021 pmid:26652232.

5. Belyaev S.A., Leontyev S.A., Mor F.-V. Transcatheter implantation of the aortic valve. Creative Cardiology N 4, 2015;4:25-33. [in Russian]. DOI:10.15275/kreatkard.2015.04.03

6. Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J., Iung B., Lancellotti P., Lansac E., Muñoz D.R., Rosenhek R., Sjögren J., Tornos Mas P., Vahanian A., Walther T., Wendler O., Windecker S., Zamorano J.L.; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. Eur. Heart J., 2017 Sep 21;38(36):2739–2791. DOI:10.1093/eurheartj/ehx391

7. Reardon M.J., Van Mieghem N.M., Popma J.J. et. al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients The new England journal of medicine. 2017;376:1321-31. DOI:10.1056/NEJMoa1700456.

8. Leon M.B., Smith C.R., Mack M.J. et al. PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609–1620. DOI:10.1056/NEJMoa1514616

9. Gehlot A., Mullany C.J., Ilstrup D. et al. Aortic valve replacement in patients aged eighty years and older: early and long-term results. J Thorac Cardiovasc Surg. 1996. 111(5):1026-36. DOI:10.1016/S0022-5223(96)70379-3

10. Sundt T.M., Bailey M.S., Moon M.R., et al. Quality of life after aortic valve replacement at the age of >80 years. Circulation. 2000, Nov. 7;102(19 Suppl. 3):III70-4. DOI:10.1161/01.CIR.102.suppl_3.III-70

11. Cribier A., Eltchaninoff H., Bash A., et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002. 106:3006-3008. DOI:10.1161/01.CIR.0000047200.36165.B8

12. Vahl T.P., Kodali S.K., Leon M.B. Transcatheter aortic valve replacement 2016: A modern-day “through the lookingglass – adventure. J Am Coll Cardiol. 2016;67:1472–87. DOI:10.1016/j.jacc.2015.12.059.

13. Holmes D.R. Jr., Nishimura R.A., Grover F.L., Brindis R.G., Carroll J.D., Edwards F.H., Peterson E.D., Rumsfeld J.S., Shahian D.M., Thourani V.H., Tuzcu E.M., Vemulapalli S., Hewitt K., Michaels J., Fitzgerald S., Mack M.J.; STS/ACC TVT Registry. Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. Ann Thorac Surg. 2016;101:789-800. DOI:10.1016/j.athoracsur.2015.10.049

14. Wenaweser P., Stortecky S., Heg D., Tueller D., Nietlispach F., Falk V., Pedrazzini G., Jeger R., Reuthebuch O., Carrel T. Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry. EuroIntervention. 2014;10:982-989. DOI:10.4244/EIJV10I8A166

15. Haude M. [Management of valvular heart disease: ESC/EACTS guidelines 2017].

16. Bosmans J.M., Kefer J., De Bruyne B., Herijgers P. et al., Belgian TAVI Registry Participants. Procedural, 30-day and one year outcome following 141 CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry. Interact Cardiovasc Thorac Surg. 2011; 12(5):762-767. DOI:10.1510/icvts.2010.253773

17. Kappetein A.P., Head S.J., Treede H. et al. What is the evidence allowing us to state that transcatheter aortic valve replacement via the femoral artery is a more attractive option compared to transapical valve replacement? EuroIntervention, 2011; 7:903–904. DOI:10.1016/j.jacc.2016.10.024

18. Reardon M.J., Adams D.H., Kleiman N.S. et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol., 2015:66(2):113-21. DOI:10.1016/j.jacc.2015.05.017